Seasonal Influenza Vaccines

  • ID: 4335315
  • Report
  • 134 Pages
  • Datamonitor Healthcare
1 of 4
Global Vaccination Rates Remain Lower than the Levels Recommended by the World Health Organization

Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates. Seasonal influenza can be type A, B, or C. Type A influenza viruses are considered to be the most virulent of the three types and can be further classified by serotype based on antibody response to the virus.

Seasonal influenza presents significant public health problems for nearly every country, largely because of the cost associated with the treatment or management of the disease, as well as the toll on the workforce. Vaccination against seasonal influenza is the most effective method of preventing influenza infection. However, global vaccination rates remain lower than the levels recommended by the World Health Organization.

Recent events and opinion:

  • Quadrivalent vaccines are seeing rapid uptake and will gradually replace trivalent vaccines in all patient groups in the US and EU markets
  • The broadening of recommendations to include school-aged children will drive EU market growth significantly
  • Adjuvanted vaccines in development have the potential to address unmet needs in infants and the elderly
Note: Product cover images may vary from those shown
2 of 4

Forecast: Seasonal Influenza Vaccines

Executive Summary

  • Market Overview and Trends
  • Key Drivers and Resistors of Conversion to QIVs
  • Market Definition
  • US Market Forecast
  • France Market Forecast
  • Germany Market Forecast
  • Italy Market Forecast
  • Spain Market Forecast
  • UK Market Forecast

Marketed Drugs: Seasonal Influenza Vaccines

  • Executive Summary
  • Product Overview
  • Product profile: FluMist QIV
  • Product profile: Flucelvax QIV
  • Product profile: Fluzone High-Dose

Pipeline: Seasonal Influenza Vaccines

  • Executive Summary
  • Clinical Pipeline Overview
  • Product profile (late stage): Fluad QIV

List of Figures:
Figure 1: Total sales of seasonal influenza vaccines across the US and five major EU markets, by country, 2016/17-2025/26
Figure 2: Key drivers and resistors of conversion to QIVs
Figure 3: Total sales of seasonal influenza vaccines across the US and five major EU markets, by class, 2016/17-2025/26
Figure 4: Patient-based forecasting methodology for seasonal influenza vaccines
Figure 5: Price sources and calculations in the EU, by country
Figure 6: Total sales of seasonal influenza vaccines in the US, by class, 2016/17-2025/26
Figure 7: Total seasonal influenza vaccination coverage in the US, by risk group, 2016/17-2025/26
Figure 8: Total sales of seasonal influenza vaccines in France, by class, 2016/17-2025/26
Figure 9: Total seasonal influenza vaccination coverage in France, by risk group, 2016/17-2025/26
Figure 10: Total sales of seasonal influenza vaccines in Germany, by class, 2016/17-2025/26
Figure 11: Total seasonal influenza vaccination coverage in Germany, by risk group, 2016/17-2025/26
Figure 12: Total sales of seasonal influenza vaccines in Italy, by class, 2016/17-2025/26
Figure 13: Total seasonal influenza vaccination coverage in Italy, by risk group, 2016/17-2025/26
Figure 14: Total sales of seasonal influenza vaccines in Spain, by class, 2016/17-2025/26
Figure 15: Total seasonal influenza vaccination coverage in Spain, by risk group, 2016/17-2025/26
Figure 16: Total sales of seasonal influenza vaccines in the UK, by class, 2016/17-2025/26
Figure 17: Total seasonal influenza vaccination coverage in the UK, by risk group, 2016/17-2025/26
Figure 18: FluMist QIV for seasonal influenza - SWOT analysis
Figure 19: Flucelvax QIV for seasonal influenza - SWOT analysis
Figure 20: Fluzone High-Dose for seasonal influenza - SWOT analysis
Figure 21: Fluad QIV for seasonal influenza - SWOT analysis

List of Tables:
Table 1: Recommendations for influenza vaccination by national authorities, by country, 2016-17
Table 2: Approved and pipeline QIVs
Table 3: Development status of Fluarix Tetra and FluMist QIV/Fluenz Tetra in the US and five major EU markets, 2016/17
Table 4: Total influenza coverage rates in the US compared to the five major EU markets, 2016/17-2025/26
Table 5: US seasonal influenza vaccines market forecast, 2016/17-2025/26
Table 6: US vaccination coverage rates in recommended risk groups, 2016/17-2025/26
Table 7: France seasonal influenza vaccines market forecast, 2016/17-2025/26
Table 8: France vaccination coverage rates in recommended risk groups, 2016/17-2025/26
Table 9: Germany seasonal influenza vaccines market forecast, 2016/17-2025/26
Table 10: Germany vaccination coverage rates in recommended risk groups, 2016/17-2025/26
Table 11: Italy seasonal influenza vaccines market forecast, 2016/17-2025/26
Table 12: Italy vaccination coverage rates in recommended risk groups, 2016/17-2025/26
Table 13: Spain seasonal influenza vaccines market forecast, 2016/17-2025/26
Table 14: Spain vaccination coverage rates in recommended risk groups, 2016/17-2025/26
Table 15: UK seasonal influenza vaccines market forecast, 2016/17-2025/26
Table 16: UK vaccination coverage rates in recommended risk groups, 2016/17-2025/26
Table 17: Key marketed vaccines for seasonal influenza
Table 18: FluMist QIV drug profile
Table 19: FluMist QIV pivotal trial data in seasonal influenza
Table 20: FluMist TIV Phase III data
Table 21: Flucelvax QIV drug profile
Table 22: Flucelvax QIV pivotal trial data in seasonal influenza
Table 23: Fluzone High-Dose drug profile
Table 24: Fluzone High-Dose pivotal trial data in seasonal influenza
Table 25: Fluzone High-Dose late-phase trial data in seasonal influenza
Table 26: Phase III pipeline vaccines in development for seasonal influenza
Table 27: Fluad QIV drug profile
Table 28: Fluad QIV Phase III trials in seasonal influenza

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll